Materias dentro de su búsqueda.
Mostrando 261 - 280 Resultados de 3,294 Para Buscar '"gout"', tiempo de consulta: 0.11s Limitar resultados
  1. 261
    “…IMPORTANCE: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a lower risk of incident gout; however, their association with recurrent flares is unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
  2. 262
    “…The effect size of ABCG2 rs2231142 on urate is ~ 60% that of SLC2A9, yet the effect size on gout is greater. We tested the hypothesis that ABCG2 plays a role in the progression from HU to gout by testing for association of ABCG2 rs2231142 and rs10011796 with gout using HU controls. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
  3. 263
    “…BACKGROUND: To use a gout-specific quality of life (QoL) tool, the Gout Impact Scale (GIS), to evaluate characteristics of gout affecting QoL in subjects with gout. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of the Gout Impact Scale to Evaluate Quality of Life in Chinese Subjects with Gout: A Cross-Sectional Study
  4. 264
    “…OBJECTIVES: Gout flares are painful and disabling. We developed a smartphone application (app) for patients to tele-monitor gout flares surveyed by clinicians. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tele-monitoring flares using a smartphone app in patients with gout or suspected gout: a feasibility study
  5. 265
    “…OBJECTIVES: To determine the effect of omega-three supplementation with fish oil on serum urate, weight and body mass index (BMI) in people with gout. METHODS: A pilot 6-month, randomized, open-label clinical trial was undertaken in people with gout with serum urate ≥ 0.36 mmol/l. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial
  6. 266
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SNP-based heritability estimates of gout and its subtypes determined by genome-wide association studies of clinically defined gout
  7. 267
    “…OBJECTIVES: In patients with gout there is a lack of longitudinal studies on the course of work productivity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
  8. 268
    “…OBJECTIVE: Gout is associated with lifestyle, body mass index (BMI) and comorbidities, including dyslipidaemia. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
  9. 269
    “…BACKGROUND: Dual-energy computed tomography (DECT) is a new diagnostic tool for gout, but its sensitivity has not been established. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout
  10. 270
    “…This clinical audit of two cohorts of gout patients provides initial—yet promising—results regarding the proportion of real-world gout patients in whom recommended that sUA target levels can be achieved, and demonstrates the added value that a targeted treatment approach may have in reaching these goals.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
  11. 271
    “…Gout is the most common inflammatory arthritis which is caused by the buildup of uric acid crystals in the joints, that leads to severe pain, swelling, and stiffness. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Atypical Presentation of Gout: A Case Report
  12. 272
    por Burnier, Michel
    Publicado 2023
    “…Gout and hyperuricaemia are two clinical situations associated with an elevated risk of developing cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and renal complications. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gout and hyperuricaemia: modifiable cardiovascular risk factors?
  13. 273
    “…Infused biologics, such as pegloticase, are a core component of managing uncontrolled gout, which is increasing in prevalence. Pegloticase is often the last line of therapy for patients with uncontrolled gout; therefore, achieving a successful course of treatment is critical. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
  14. 274
    “…We present a case of perforating tophaceous gout, which underscores the need for a thoughtful approach to perforating disorders. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Perforating Gout: Expanding the Differential for Transepidermal Elimination
  15. 275
    “…Gout arthritis is an inflammatory condition that occurs suddenly in joints affected by high uric acid levels (hyperuricemia). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The inflammation process of gout arthritis and its treatment
  16. 276
    “…INTRODUCTION: Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Adherence with urate-lowering therapies for the treatment of gout
  17. 277
    “…Treatment-failure gout (TFG) affects approximately 50,000 patients or about 1% of the overall population of patients with gout in the United States of America. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    New advances in the treatment of gout: review of pegloticase
  18. 278
    por Singh, Jasvinder A
    Publicado 2010
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Advances in gout: some answers, more questions
  19. 279
    “…INTRODUCTION: The objective of this study was to investigate the contemporary incidence of gout, examine potential risk factors, and evaluate specific gout treatment patterns in the general population. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Contemporary epidemiology of gout in the UK general population
  20. 280
    por Nuki, George, Simkin, Peter A
    Publicado 2006
    “…First identified by the Egyptians in 2640 BC, podagra (acute gout occurring in the first metatarsophalangeal joint) was later recognized by Hippocrates in the fifth century BC, who referred to it as 'the unwalkable disease'. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A concise history of gout and hyperuricemia and their treatment
Herramientas de búsqueda: RSS